Table 3.
Continuous Baseline Measures by POAG Outcome for OHTS Observation Group and EGPS Placebo Group
| Study Group | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OHTS Observation | EGPS Placebo | OHTS and EGPS Control Groups | ||||||||||
| Developed POAG | Developed POAG | Developed POAG | ||||||||||
| No | Yes | No | Yes | No | Yes | |||||||
| N | Mean ± Std | N | Mean ± Std | N | Mean ± Std | N | Mean ± Std | N | Mean ± Std | N | Mean ± Std | |
| Age | 708 | 55.4 ± 9.7 | 104 | 58.2 ± 9.2 | 439 | 57.2 ± 10.0 | 61 | 61.1 ± 9.9 | 1147 | 56.1 ± 9.9 | 165 | 59.3 ± 9.5 |
| Mean IOP | 708 | 25.0 ± 2.0 | 104 | 26.0 ± 2.3 | 439 | 22.3 ± 2.0 | 61 | 22.9 ± 2.1 | 1147 | 24.0 ± 2.4 | 165 | 24.9 ± 2.7 |
| Mean CCT* | 615 | 578.1± 36.8 | 102 | 551.2 ± 36.0 | 357 | 574.9 ± 34.6 | 54 | 549.9 ± 37.3 | 972 | 577.0 ± 36.0 | 156 | 550.7 ± 36.3 |
| Mean Vertical C/D ratio* (By Contour) | 708 | 0.38 ± 0.2 | 104 | 0.47 ± 0.2 | 438 | 0.31 ± 0.1 | 61 | 0.36 ± 0.1 | 1146 | 0.35 ± 0.2 | 165 | 0.43 ± 0.2 |
| Mean PSD* (dB) | 708 | 1.90 ± 0.2 | 104 | 1.94 ± 0.2 | 437 | 2.00 ± 0.5 | 59 | 2.12 ± 0.5 | 1145 | 1.94 ± 0.4 | 163 | 2.01 ± 0.4 |
| Mean Mean Defect* (dB) | 708 | 0.23 ± 1.0 | 104 | 0.13 ± 1.0 | 437 | 0.10 ± 1.5 | 59 | 0.09 ± 1.5 | 1145 | 0.18 ± 1.2 | 163 | 0.12 ± 1.2 |
| Mean CPSD* (dB) | 708 | 1.11 ± 0.4 | 104 | 1.17 ± 0.4 | 370 | 1.06 ± 0.6 | 53 | 0.98 ± 0.7 | 1078 | 1.10 ± 0.5 | 157 | 1.11 ± 0.5 |
| Mean Refraction* (Spherical Equivalent) | 708 | −0.60 ± 2.3 | 104 | −0.60 ± 2.6 | 439 | 0.25 ± 1.7 | 61 | 0.51 ± 1.3 | 1147 | −0.27 ± 2.1 | 165 | −0.19 ± 2.3 |
*
Eye-specific variables are the mean of the right and left eyes for each participant
CCT Central corneal thickness
C/D Cup-to-disc ratio
CPSD Corrected pattern standard deviation
dB Decibel
OHTS Ocular Hypertension Treatment Study
EGPS European Glaucoma Prevention Study
IOP Intraocular pressure
POAG Primary open angle glaucoma
PSD Pattern standard deviation
Std Standard deviation